Feb 4, 2026
The House of Lords Public Services Committee has published its report concluding its medicines security inquiry. They argued that it is vital that the UK has strong, resilient medicine supply chains and emphasised the need for clear, proactive leadership. The report...
Jan 7, 2026
To start the year off with a bang, we thought we’d compare the generic product prices we get from our Pharmacy and Dispensing Doctor data suppliers with the Drug Tariff for each product. This obviously excludes some products where there is no Drug Tariff...
Oct 16, 2025
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus. The average market price for this medicine normally hovers around the £5 mark but in late 2019 the drug tariff started to come down from over £10.42...
Sep 16, 2025
Leslie Galloway, EMIG Chairman, shared his analysis of VPAG. Here’s Charles’ key takeaways: · The NHS VPAG rebate is £1bn over 3 years and so is a fixed rebate with risk share. · Global Pharma CEOs have asked for lower rebates and a better deal, that...
Sep 16, 2025
Charles Joynson, WaveData MD, decided to have a look at the differences between the average market price for generics and the English drug tariff. He wanted to know if the gap between the two was being squeezed, resulting in some of the misery pharmacists are going...
Sep 16, 2025
Four times over the last 10 years, free market competition between the manufacturers of Olanzapine tablets drove the price to a level where profit was impossible and withdrawal is the only option. When prices decline in the market, the reimbursement drug tariff often...
